ABT vs EW
ABT: Abbott is a diversified healthcare conglomerate manufacturing diagnostics, nutritional products, pharmaceuticals, and medical devices with recent expansion into cancer diagnostics through Exact Sciences acquisition. EW: Global leader in transcatheter heart valve therapies and structural heart repair technologies, treating the world's leading cause of death with minimally invasive solutions.
Side-by-side fundamentals
| Metric | ABT | EW | Edge |
|---|---|---|---|
| Price as of 2026-07-15 close | $89.27 | $87.27 | |
| Market cap as of 2026-07-16 | $156.2B | $50.9B | |
| P/E as of 2026-07-16 | 24.88 | 46.42 | ABT lower |
| PEG as of 2026-07-16 | 2.66 | 2.13 | EW lower |
| Net margin as of 2026-07-16 | +13.9% | +17.4% | EW higher |
| Gross margin as of 2026-07-16 | +56.5% | +77.9% | EW higher |
| Operating margin as of 2026-07-16 | +17.1% | +17.1% | ABT higher |
| ROE as of 2026-07-16 | +12.2% | +10.6% | ABT higher |
| ROA as of 2026-07-16 | +6.9% | +8.2% | EW higher |
| Debt / equity as of 2026-07-16 | 0.65 | 0.06 | EW lower |
| Revenue growth (YoY) as of 2026-07-16 | +6.6% | +13.8% | EW higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +10.8% | EW higher |
| Dividend yield as of 2026-07-16 | +2.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-07-16 | 0.60 | 0.83 | |
| 1-year return as of 2026-07-15 close | -32.6% | +15.1% | EW higher |
Fundamentals: Finnhub, as of 2026-07-16. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-15.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.